Recognizing OFF Time in Parkinson’s Disease

In ‘Recognizing OFF Time in Parkinson’s Disease,’ our panel explores how motor fluctuations begin to emerge as Parkinson’s disease progresses and oral medications become less consistent. The expert neurologist and patient discuss how changes in medication response, including delayed onset and shorter duration of benefit, signal the development of OFF time. Contributing factors such as gastrointestinal changes and stress are highlighted as key elements that can further complicate symptom control and lead to variability in treatment response.

The patient described that the early experience of OFF time was marked by frustration, uncertainty, and a lack of awareness about what was happening. Symptoms such as delayed medication effect in the morning and earlier wearing off throughout the day disrupted routine and reduced functional independence. They reflect on initially underreporting symptoms during clinical visits, often presenting while feeling well and minimizing challenges experienced at home. This gap in communication delayed treatment adjustments and underscores how easily OFF time can go unrecognized without proactive dialogue.

The discussion emphasized the essential role of caregivers and transparent communication in optimizing care. The patient describes how involvement from a care partner provided critical insight into daily functioning, helping the clinician better understand the full impact of symptoms. The expert neurologist reinforces that patients may unintentionally downplay symptoms due to pride, misunderstanding, or fear of disappointing their physician. Together, the panel highlights that open, honest communication and caregiver engagement are fundamental to identifying OFF time early and improving long-term outcomes in Parkinson’s disease.

Our next episode, ‘Understanding OFF Time in Parkinson’s Disease,’ explores how patients and clinicians define and experience OFF time, along with the underlying causes of motor fluctuations. The discussion highlights both patient-reported symptoms and clinical insights into disease progression and treatment response.